Combined Stem Cell and Hormonal Therapy Stimulates Bone Growth and Repair
By LabMedica International staff writers Posted on 20 Dec 2015 |
Image: A- Labeled stem cells target spinal bone fracture; B- Two spinal bone fractures; C- Complete healing of spinal bone fractures eight weeks post treatment with stem cells and PTH (Photo courtesy of Cedars-Sinai Board of Governors Regenerative Medicine Institute).
A novel regimen to promote healing of damaged or broken bones is based on combined stem cell and hormonal treatment.
Parathyroid hormone (PTH) has been shown to induce fracture repair in animals by activating mesenchymal stem cells (MSCs). However, researchers speculated that it would be less effective in patients with fewer and/or dysfunctional MSCs due to aging and related chronic disorders. To address this issue, investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) evaluated the potential of combination intravenous MSC and PTH therapy versus monotherapy and untreated controls, in animal models of osteoporotic vertebral bone defects.
In this study, rats and pigs with vertebral fractures received daily injections of PTH for 21 days. During this period, the animals were injected with five doses of mesenchymal stem cells. Control animals received only PTH or MSC injections (monotherapy) or no treatment at all.
Results published in the November 20, 2015, online edition of the journal Molecular Therapy demonstrated that combination therapy significantly increased new bone formation versus monotherapy and no treatment by two weeks. Mechanistically, PTH significantly enhanced MSC migration to the lumbar region, where the MSCs differentiated into bone-forming cells. Thus, PTH functioned as an adjuvant to intravenous MSC therapy by enhancing migration to heal bone loss.
"We have known that used separately, both the stem cells and the hormone each have an effect on the healing process involved in bone fractures," said senior author Dr. Dan Gazit, professor of surgery at Cedars-Sinai Medical Center. "Now, we have learned that the stem cells and PTH are much stronger combined than they are separately."
Related Links:
Cedars-Sinai Medical Center
Parathyroid hormone (PTH) has been shown to induce fracture repair in animals by activating mesenchymal stem cells (MSCs). However, researchers speculated that it would be less effective in patients with fewer and/or dysfunctional MSCs due to aging and related chronic disorders. To address this issue, investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) evaluated the potential of combination intravenous MSC and PTH therapy versus monotherapy and untreated controls, in animal models of osteoporotic vertebral bone defects.
In this study, rats and pigs with vertebral fractures received daily injections of PTH for 21 days. During this period, the animals were injected with five doses of mesenchymal stem cells. Control animals received only PTH or MSC injections (monotherapy) or no treatment at all.
Results published in the November 20, 2015, online edition of the journal Molecular Therapy demonstrated that combination therapy significantly increased new bone formation versus monotherapy and no treatment by two weeks. Mechanistically, PTH significantly enhanced MSC migration to the lumbar region, where the MSCs differentiated into bone-forming cells. Thus, PTH functioned as an adjuvant to intravenous MSC therapy by enhancing migration to heal bone loss.
"We have known that used separately, both the stem cells and the hormone each have an effect on the healing process involved in bone fractures," said senior author Dr. Dan Gazit, professor of surgery at Cedars-Sinai Medical Center. "Now, we have learned that the stem cells and PTH are much stronger combined than they are separately."
Related Links:
Cedars-Sinai Medical Center
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples